However, 4.6 and 8.4% of FIDELIO-DKD and FIGARO-DKD were using SGLT-2 inhibitors at baseline, and the beneficial renal effects of finerenone, compared with placebo, appeared to be at least as beneficial among people using versus not using SGLT-2 inhibitors [226]. Here, SLC5A2 is linked to diabetic kidney disease.